Discussions Regarding Reproductive Health for Young Women With Breast Cancer Undergoing Chemotherapy

Duffy, Christine; Allen, Susan; Clark, Melissa A.

doi:10.1200/jco.2005.01.134

Cited by 178 publications

(155 citation statements)

References 51 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…Previous surveys of breast cancer survivors have demonstrated that a large proportion of patients do not recall their doctors having discussed with them the risks of early menopause and infertility prior to the onset of adjuvant cancer treatment [26]. Such retrospective surveys are subject to recall bias, especially as discussions take place at a time when patients may not be able to process the information they receive [27].…”

Section: Resultsmentioning

confidence: 99%

Fertility preservation in women undergoing treatment for breast cancer in the UK: A questionnaire study

King

Roche

Davies

et al. 2012

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Objective. Fertility preservation is an important survivorship issue for women treated for breast cancer. The aim of this work was to examine the referral practices of health care professionals who treat women with breast cancer in the United Kingdom, and to investigate their understanding and knowledge of the fertility preservation options available.Method. An invitation to participate in a confidential, online questionnaire was e-mailed to surgeons, oncologists, and clinical nurse specialists who manage patients with breast cancer in the United Kingdom.Results. n ‫؍‬ 306 respondents. Factors which influenced whether fertility preservation options were discussed with a patient included the following: patient's age (78%), final tumor/nodes/metastasis status (37.9%); concern that fertility preservation would delay chemotherapy (37.3%); whether the patient had children (33.5%) or a partner (24.7%); estrogen receptor expression (22.6%), lack of knowledge regarding the available options (20.9%); and concern that fertility preservation would compromise the success of cancer treatment (19.8%). Twenty-seven percent did not know whether fertility preservation was available for their patients on the National Health Service. Nearly half (49.4%) of respondents said that gonadotropin-releasing hormone agonists were used for fertility preservation outside the setting of a clinical trial. Knowledge regarding the available options varied according to different members of the multidisciplinary team, with consultant oncologists better informed than consultant surgeons or clinical nurse specialists (p < .05).Conclusions. Many health care professionals have incomplete knowledge regarding the local arrangements for fertility preservation for patients with breast cancer. This may result in patients receiving inadequate or conflicting information regarding fertility preservation. The Oncologist 2012;17:910 -916

show abstract

Section: Resultsmentioning

confidence: 99%

Fertility preservation in women undergoing treatment for breast cancer in the UK: A questionnaire study

King

Roche

Davies

et al. 2012

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…It has been reported in a US study, that 45 % of oncologists did not routinely discuss fertility preservation treatment with women of reproductive age [15] despite infertility being rated as one of the most important issues amongst women with cancer [11]. There are various factors contributing to this referral barrier.…”

Section: Discussionmentioning

confidence: 99%

“…Fertility preservation is an important part of the multidisciplinary management of cancer in reproductive-aged women, given the known gonadotoxity of various chemo/radiotherapy regimens and patients' concern for their future fertility [11]. Although the incidence of cancer increases with age, a significant proportion of cancer diagnoses are made in young women of reproductive age.…”

Section: Introductionmentioning

confidence: 99%

Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation

Barcroft

Dayoub

Thong

2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Determine the outcome of embryo cryopreservation in female oncology patients Methods The outcomes of IVF/ICSI cycles in oncology patients over 15 years in a University Teaching Hospital. Results Forty-two oncology patients (mean 31.9±3.9 years) underwent embryo cryopreservation treatment (n=33 IVF, n=6 ICSI). Controlled ovarian stimulation with GnRH antagonist protocol (n=34; 81 %) yielded fewer oocytes than GnRH agonist protocol (n=8; 19 %) (9.4±6.3 vs. 15.3±8.9; p=0.04) respectively. There was no significant difference in mean (±SD) duration of ovarian stimulation (11.6±2.6 vs.10.6±2.7), median gonadotrophin dose (1950( vs. 1670, median day 5-6 oestradiol level (1124 vs.1129 pmol/l) or embryo yield (6.2±4.1 vs. 8.8± 4.3; p=0.07) between GnRH antagonist and agonist treatment cycles respectively. Thirty-nine patients cryopreserved embryos and three had their cycle cancelled. During this study period, of those who cryopreserved embryos, 5 patients underwent 9 frozen-thaw cycles (13 %), resulting in 2 live births (1 twin, 1 singleton, live birth rate 22 %). Six patients died (15 %), 3 conceived naturally (8 %) and 2 couples separated (5 %). Fourteen patients discarded their embryos (36 %). Twenty-two patients' (56 %) have embryos remaining in storage. Conclusions This study demonstrates that embryo cryopreservation in female oncology patients gives a satisfactory live birth rate. However, there are concerns regarding costeffectiveness, resulting from high disposal/non-usage of embryos, and further studies are required.

show abstract

“…Canadian fertility specialists have perceived both inadequate education and inadequate awareness of infertility risk, together with a lack of support from oncology providers, as the top reasons for poor referral volumes 3 . Among 1093 postpubertal patients, male and female, the rates of physician-led fertility preservation discussions varied from as low as 34% to 86% [26][27][28][29] . Furthermore, patients rely on endorsement from their oncology health care providers in deciding whether to pursue fertility preservation 25,27,30 , even with multiple knowledge resources in place 31 .…”

Section: Patient Knowledgementioning

confidence: 99%

Oncofertility in Canada: An Overview of Canadian Practice and Suggested Action Plan

Ronn

Holzer

2013

Current Oncology

View full text Add to dashboard Cite

Background: Cancer can be a devastating diagnosis. In particular, malignancy and its indicated treatments have profoundly negative effects on the fertility of young cancer patients. Oncofertility has emerged as a new interdisciplinary field to address the issue of gonadotoxicity associated with cancer therapies and to facilitate fertility preservation. In Canada, these fertility issues are often inadequately addressed despite the availability of resources. The goal of this four-part series is to facilitate systemic improvements in fertility preservation for adolescent and young adult Canadians with a new diagnosis of cancer. Methods: Here, we describe the services currently available in Canada and the challenges associated with their utilization. Finally, we outline strategies to help maximize and facilitate fertility preservation in the young cancer patient. Results: Despite an existing infrastructure to the oncofertility system in Canada, the ability of that system’s components to function together and to coordinate patient care is a challenge. Areas of weakness include poor access and referral to fertility services, a lack of readily available education for patients and health care providers, and inconsistent interdisciplinary coordination in patient care. Conclusions: The implementation of a framework for multidisciplinary resource allocation, education, patient referral, and established lines of communication may facilitate a functional oncofertility system in Canada.

show abstract

Discussions Regarding Reproductive Health for Young Women With Breast Cancer Undergoing Chemotherapy

Cited by 178 publications

References 51 publications

Fertility preservation in women undergoing treatment for breast cancer in the UK: A questionnaire study

Fertility preservation in women undergoing treatment for breast cancer in the UK: A questionnaire study

Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation

Oncofertility in Canada: An Overview of Canadian Practice and Suggested Action Plan

Contact Info

Product

Resources

About